Modified Glasgow Prognostic Score is predictive of prognosis for non-small cell lung cancer patients treated with stereotactic body radiation therapy: a retrospective study

• Published in: Journal of radiation research 2021-05, Vol.62 (3), p.457-464
• Main Authors: Chen, Zhe, Nonaka, Hotaka, Onishi, Hiroshi, Nakatani, Eiji, Sato, Yoko, Funayama, Satoshi, Watanabe, Hiroaki, Komiyama, Takafumi, Kuriyama, Kengo, Marino, Kan, Aoki, Shinichi, Araya, Masayuki, Tominaga, Licht, Saito, Ryo, Maehata, Yoshiyasu, Oguri, Mitsuhiko, Saito, Masahide
• Format: Article
• Language: English
• Subjects: Cancer; Development and progression; Lung cancer, Non-small cell; Lung cancer, Small cell; Oncology, Experimental; Oncology/Medicine; Prognosis; Radiation; Radiotherapy
• ISSN: 0449-3060; 1349-9157
• DOI: 10.1093/jrr/rrab021

We aimed to assess the predictive value of the modified Glasgow prognostic score (mGPS) in patients with non-small cell lung cancer (NSCLC) who underwent stereotactic body radiation therapy (SBRT). We retrospectively reviewed the records of 207 patients, with a median age of 79 years. The pretreatment mGPS was calculated and categorized as high (mGPS = 1-2) or low (mGPS = 0). The median follow-up duration was 40.7 months. The five-year overall survival (OS), progression-free survival (PFS) and time to progression (TTP) rates were 44.3%, 36% and 54.4%, respectively. Multivariate analysis revealed that mGPS was independently predictive of OS (hazard ratio [HR] 1.67; 95% confidence interval 1.14-2.44: P = 0.009), PFS (HR 1.58; 1.10-2.28: P = 0.014) and TTP (HR 1.66; 1.03-2.68: P = 0.039). Patients who had high mGPS showed significantly worse OS (33.3 vs 64.5 months, P = 0.003) and worse PFS (23.8 vs 39 months, P = 0.008) than those who had low mGPS. The data showed a trend that patients with high mGPS suffered earlier progression compared to those with low mGPS (54.3 vs 88.1 months, P = 0.149). We confirmed that mGPS is independently predictive of prognosis in NSCLC patients treated with SBRT.